Enrico Giovanelli Toccani Gimenez

Enrico Giovanelli Toccani Gimenez

Auto-generated profile, based on publicly available information

Enrico Giovanelli Toccani Gimenez

Laboratory of Cellular and Molecular Genetics, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2023 in Probiotics and Antimicrobial Proteins
Verified
Journal Article
Closed access
PDF file
Juan Carlos Ariute OliveiraJuan Carlos Ariute Oliveira
Juan Carlos Ariute Oliveira
NRNina Coelho Rocha
Nina Coelho Rocha
CDCarlos Willian Dias Dantas
Carlos Willian Dias Dantas
LVLarissa Amorim Tourinho de Vasconcelos
Larissa Amorim Tourinho de Vasconcelos
RPRodrigo Profeta
Rodrigo Profeta
Flavia AburjaileFlavia Aburjaile
Flavia Aburjaile

19 January 2021 in PLOS Neglected Tropical Diseases
Verified
Journal Article
Open access
PDF file
Fábio MambelliFábio Mambelli
Fábio Mambelli
BSBruno de Paula Oliveira Santos
Bruno de Paula Oliveira Santos
SMSuellen B. Morais
Suellen B. Morais
EGEnrico G. T. Gimenez
Enrico G. T. Gimenez
DADuana C. dos S. Astoni
Duana C. dos S. Astoni
Sergio Costa OliveiraSergio Costa Oliveira
Sergio Costa Oliveira
TheSchistosoma mansoni SmKI-1 protein is composed of two domains: a Kunitz-type serine protease inhibitor motif (KD) and a C-terminus domain with no similarity outside the genera. Our previous work has demonstrated that KD plays an essential role in neutrophil elastase (NE) binding blockage, in neutrophil influx and as a potential anti-inflammatory molecule. In order to enhance NE blocking capacity, we analyzed the KD sequence from a structure-function point of view and designed specific point mutations in order to enhance NE affinity. We substituted the P1 site residue at the reactive site for a leucine (termed RL-KD), given its central role for KD’s inhibition to NE. We have also substituted a glutamic acid that strongly interacts with the P1 residue for an alanine, to help KD to be buried on NE S1 site (termed EA-KD). KD and the mutant proteins were evaluatedin silicoby molecular docking to human NE, expressed inEscherichia coliand tested towards its NE inhibitory activity. Both mutated proteins presented enhanced NE inhibitory activityin vitroand RL-KD presented the best performance. We further tested RL-KDin vivoin an experimental model of monosodium urate (MSU)-induced acute arthritis. RL-KD showed reduced numbers of total cells and neutrophils in the mouse knee cavity when compared to KD. Nevertheless, both RL-KD and KD reduced mice hypernociception in a similar fashion. In summary, our results demonstrated that both mutated proteins showed enhanced NE inhibitory activityin vitro. However, RL-KD had a prominent effect in diminishing inflammatory parametersin vivo.